1. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
   Satoshi Igawa et al, 2022, Investigational New Drugs CrossRef
2. Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
   Soon Hin How et al, 2022, Cancer Management and Research CrossRef
3. Lung Adenocarcinoma in a Patient with a Reduced Performance Status due to Carcinomatous Meningitis That Showed a Remarkable Response to Osimertinib: a Case Report
   Kotaro Murao et al, 2021, Haigan CrossRef
4. Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature
   Akinori Sasaki et al, 2023, Journal of Medical Case Reports CrossRef
5. The Presence of Genomic Instability in Cerebrospinal Fluid in Patients with Meningeal Metastasis
   Peng Wang et al, 2021, Cancer Management and Research CrossRef